IMEIK's revenue in 2025 is 2.45 billion, a year-on-year decrease of 19%, with a net profit of 1.1 billion after deducting non-recurring items, down 41%

Leidi Network, Jianping Lei, March 21 "Medical Beauty Moutai" IMEIK Technology Development Co., Ltd. (stock code: 300896, stock abbreviation: IMEIK) recently released its annual report for the year ending December 31, 2025. The annual report shows that IMEIK's revenue in 2025 is 2.453 billion yuan, a decrease of 18.94% compared to 3.026 billion yuan in the same period last year. IMEIK's net profit in 2025 is 1.291 billion yuan, a decrease of 34% compared to 1.958 billion yuan in the same period last year; the net profit after deducting non-recurring items is 1 billion yuan, a decrease of 41.3% compared to 1.872 billion yuan in the same period last year. IMEIK's revenue in 2023 is 2.869 billion yuan, with a net profit of 1.858 billion yuan and a net profit of 1.831 billion yuan after deducting non-recurring items. It can be seen that IMEIK's revenue and profit in 2025 are far below those of the previous two years. IMEIK's revenue in the fourth quarter of 2025 is 588 million yuan, with a net profit of 200 million yuan and a net profit of 146 million yuan after deducting non-recurring items. Jian Jun received a cash dividend of 74.4 million yuan. As of December 31, 2025, Jian Jun holds 31.09% of the shares, Xiamen Zhixingjun Investment Management Partnership (Limited Partnership) holds 6.42%, Shi Yifeng and Xiamen Danrui Investment Partnership hold 4.85% each, and Xiamen Kezhishang Investment Partnership (Limited Partnership) holds 4.28%; As of December 31, 2025, IMEIK's equity structure Yuan Feng holds 3.29%, Wang Lanzhu holds 3.05%, Jian Yong holds 2.43%, Hong Kong Central Clearing Limited holds 1.54%, and Bank of China Limited - Hua Bao Zhong Zheng Medical Exchange-Traded Open-Ended Index Securities Investment Fund holds 1.54% Jian Jun and Jian Yong are siblings. Shi Yifeng is the executive managing partner of Xiamen Zhixin Junxing Investment Partnership (Limited Partnership), Xiamen Danrui Investment Partnership (Limited Partnership), and Xiamen Kezhishang Investment Partnership (Limited Partnership). As of June 30, 2025, Jian Jun holds 31.09% of the shares, Xiamen Zhixing Jun Investment Management Partnership (Limited Partnership) holds 6.42%, Shi Yifeng and Xiamen Danrui Investment Partnership hold 4.85% each, and Xiamen Kezhishang Investment Partnership (Limited Partnership) holds 4.28%; As of June 30, 2025, the equity structure of IMEIK Yuan Feng holds 3.29%, Wang Lanzhu holds 3.05%, Jian Yong holds 2.43%, Hong Kong Central Clearing Limited holds 2.31%, and Bank of China Limited - Huabao CSI Medical ETF holds 1.67%. Overall, the equity structure of IMEIK remains relatively stable in the second half of 2025. IMEIK will distribute a cash dividend of 8 yuan (tax included) for every 10 shares to all shareholders based on a total of 301,426,187 shares, with no bonus shares (tax included), and will convert 0 shares from the capital reserve to all shareholders for every 10 shares. Based on this calculation, the scale of the cash dividend distribution is 240 million yuan, and the actual controller Jian Jun can receive 74.4 million yuan in cash dividends. ——————————————————